RESTORE: An RCT to Evaluate the Efficacy of the Revi System
NCT ID: NCT06217328
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
150 participants
INTERVENTIONAL
2024-02-24
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To demonstrate superiority of Revi System therapy vs. non active therapy in the treatment of UUI
Treatment Arm:
Device: Revi System Subjects will be implanted with a Revi System and activation of therapy will occur \~4 weeks post implantation and continue for the duration of the study.
Control Arm:
Device: Revi System - Delayed Activation Subjects will be implanted with a Revi System and activation of therapy will be delayed until 4 months post implantation. At this time the Revi System will be activated to begin therapy and will continue for the duration of the study.
Randomization in a 1:2 ratio into either the "control group" or the "treatment group" will be performed in blocks of 3 or 6 randomly, across the study population by a central randomization system. Randomization will be stratified by investigational site.
The study will consist of the following activities:
Visit 1 - Screening
* Potential subjects with UUI, who fulfil basic criteria will be informed of the study and will be invited to sign an informed consent form.
* Demographic information (age, race, height and weight, leg circumference), medical and surgical history and concomitant medication information will be collected.
* Study candidates will be asked to fill out various questionnaires
* Patients will be asked to complete a 3- consecutive day voiding diary.
* Urine sample will be collected, blood will be drawn and a full physical examination, including a PVR measurement and uroflow (in men), will be performed.
Visit 2 - Randomization \& Implantation
* 5 ± 4 weeks after starting the diary, eligible subjects will be randomized to either the Treatment or Control (delayed activation) arms (2:1) and will undergo unilateral implantation with the BlueWind Revi System
* Collection of AE and concomitant medication will be performed
Treatment Arm:
Visit 3 - Activation
* After a recovery period of 4-weeks post implantation, subjects will attend the clinic to undergo physical examination and surgical wound check-up.
* Subjects will undergo parameter setting according to the individual patient sensations and will be trained on the use of the system.
Visits 4-11 - Treatment optimization and follow up
* Follow-up visits will be performed at 1, 2, 3, 6, 9, 12, and 24 months post system activation.
* A call visit will be performed at 18-months.
* All follow-up visits will require completion of a 3-day voiding diary by the patient before coming to the visit.
* During each clinic visit, stimulation parameters and level of treatment will be checked and adjusted as needed.
Control Arm:
• After a recovery period of 1-month post implantation, subjects will attend the clinic to undergo physical examination and surgical wound check-up.
Visit 4 - Activation
* After a recovery period of 4-weeks post implantation, subjects will attend the clinic to undergo physical examination and surgical wound check-up.
* Subjects will undergo parameter setting according to the individual patient sensations and will be trained on the use of the system.
Visits 5-12 - Treatment optimization and follow up
* Follow-up visits will be performed at 1, 2, 3, 6, 9, 12, and 24 months post system activation.
* A call visit will be performed at 18-months.
* All follow-up visits will require completion of a 3-day voiding diary by the patient before coming to the visit.
* During each clinic visit, stimulation parameters and level of treatment will be checked and adjusted as needed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Device: Revi System Treatment Arm
Subjects will be implanted with a Revi System and activation of therapy will occur \~4 weeks post implantation and continue for the duration of the study.
Revi System Treatment
The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
Device: Revi System - Delayed Activation Control Arm
Subjects will be implanted with a Revi System and activation of therapy will be delayed until 4 months post implantation. At this time the Revi System will be activated to begin therapy and will continue for the duration of the study.
Revi System - Delayed Activation
The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Revi System Treatment
The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
Revi System - Delayed Activation
The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is at least 21 years old, with no plans to become pregnant during the trial. If of child bearing potential and sexually active, negative pregnancy test and using acceptable contraception.
3. Subject has been diagnosed with UUI for at least 6 months.
4. Subject experiences a minimum of four (4) leaking episodes associated with urgency, with at least one episode per day for 2 days documented on a voiding diary for 3 consecutive days.
5. If used, subject should be on stable dose of antimuscarinics and/or beta-3 adrenergic agonists for at least 1 month prior to baseline and agree to remain on stable medication consumption until the 24-month follow-up visit.
6. If used, subject should be on a stable dose of tricyclic antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) for at least 3 months prior to baseline.
7. Subject agrees to attend all follow-up evaluations and is willing and capable to completely and accurately fill out voiding diaries and questionnaires and is willing to complete required exams and test
Exclusion Criteria
2. Subject is a high surgical risk with multiple illnesses or active general infections that expose them to excessive bleeding or delayed or non-healing wounds. This includes patients who need anticoagulation therapy that cannot be temporarily stopped for the implantation procedure.
3. Subject with BMI \>50.
4. Subject with any metal or other implant within 20cm distance of the area of BlueWind Revi implantation site.
5. Subject variation in diuretics consumption within the last 6 months.
6. Subject has received botulinum toxin injections for OAB within the past 12 months.
7. Subject with previous urinary incontinence surgery or prolapse surgery within the last 12 months.
8. Subject has had any spinal or genitourinary surgery within the last 6 months.
9. Subject had previous abdominoperineal resection of the rectum or radical hysterectomy (female)/ prostatectomy (male).
10. Subject with diagnosis of BPH with outflow/obstructive predominant symptoms.
11. Subject has skin, peripheral edema, orthopedic or neurologic anatomical limitations that preclude implantation or/and use of the device.
12. Subject with Alzheimer's, Parkinson, MS, stroke (CVI), neuropathy or injury resulting in neuropathy and/or suspected neurogenic bladder.
13. Subject has recurrent urinary tract infections (3 or more infections in the last 6 months), or presence of urinary fistula, or urinary tract obstruction such as cancer, urethral stricture or presence of urinary stone.
14. Subject with history of chemotherapy or pelvic radiotherapy that might have affected bladder control or caused neuropathies (i.e. peripheral neuropathy).
15. Male subject who have obstructive Benign Prostatic Hyperplasia (BPH) or other lower urinary tract obstructions.
16. Subject has open wounds or sores on the lower leg or foot or had previous, unhealed trauma in the implant area or has pitting edema (≥2+) in the lower leg.
17. Subject has Venous or Arterial disease/insufficiency in the lower leg or Vasculitis or dermatologic condition in the lower leg or infections near the implantation site in the lower leg.
18. Subject has a documented history of allergic response to Platinum iridium, Titanium, Zirconia, Gold, Silicone or Parylene.
19. Subject has other active implantable electronic device/s regardless of whether stimulation is ON or OFF.
20. Subject has a life expectancy of less than 1 year.
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BlueWind Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lori Fein
Role: STUDY_DIRECTOR
BlueWind Medical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Urology Specialists
Tucson, Arizona, United States
Pasadena Urology
Pasadena, California, United States
Riverside Medical Clinic
Riverside, California, United States
Florida Urology Partners
Tampa, Florida, United States
University of Chicago
Chicago, Illinois, United States
Duly Health
Lombard, Illinois, United States
Willis-Knighton Clinical Research
Shreveport, Louisiana, United States
Chesapeake Urology
Owings Mills, Maryland, United States
Specialty Clinical Research of St. Louis, LLC
St Louis, Missouri, United States
Adult and Pediatric Urology and Urogynecology
Omaha, Nebraska, United States
Montefiore Medical Center
The Bronx, New York, United States
Duke Urogynecology - Duke University
Durham, North Carolina, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Sanford Female Pelvic Medicine & Reconstructive Surgery Clinic
Sioux Falls, South Dakota, United States
Urology Partners of North Texas
Arlington, Texas, United States
University of Texas Southwestern - Department of Urology
Dallas, Texas, United States
DHR Health Institute for Research and Development
Edinburg, Texas, United States
The Urology Place
San Antonio, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
G02-CLP-0019
Identifier Type: -
Identifier Source: org_study_id